Recombinant Protein Vaccine Mycoplasma Testing

Recombinant protein vaccines are vaccines prepared using genetic engineering technology. The preparation process typically involves selecting one or more protein fragments from the target pathogen, then inserting the genes of these protein fragments into another organism (such as bacteria or yeast) to express these proteins in large quantities. These recombinant proteins can then be purified and used as the main components of the vaccine. Compared to traditional live or inactivated vaccines, recombinant protein vaccines do not contain live pathogens, so they are generally considered safer.

Mycoplasma is a special type of microorganism, neither a true bacterium nor a true virus, and its size is between that of bacteria and viruses. In the biopharmaceutical production process, especially when using mammalian cells as hosts for the preparation of recombinant protein vaccines, mycoplasma contamination is a significant issue because the presence of mycoplasma can affect the quality and safety of the drug. Therefore, mycoplasma testing of recombinant protein vaccines is a necessary quality control step.

Common mycoplasma detection methods include isolation culture method, indicator cell method, and nucleic acid method. The isolation culture method has very high detection accuracy and is considered the gold standard for mycoplasma detection, but it also has certain shortcomings, such as long detection time and limited identification of mycoplasma species. The indicator cell method utilizes the specific reaction of mycoplasma to certain cells, inoculating the sample to be tested into indicator cells and observing whether the cells exhibit corresponding changes. This method is suitable for some difficult-to-culture mycoplasma, but it also requires relatively long detection time. The nucleic acid method involves amplifying and detecting the mycoplasma that may be present in the drug sample to determine if the drug is contaminated. The nucleic acid method is fast, with high specificity and sensitivity, and is currently widely used to detect mycoplasma contamination in recombinant protein vaccines.

Bioproduct CharacterizationMycoplasma TestingIllustrationDiagram

Biotech Pack (BTP) adoptsISO9001certified quality control system to manage laboratories, recognized byCNASlaboratory accreditation, providing drug quality research services that comply with global pharmaceutical regulations.Webased on the existing experimental platform, offer youone-stopmycoplasma detection services for recombinant protein vaccines,just tell us your experimental objectives and send samples. Biotech Pack is responsible for all subsequent projects, including sample processing, machine analysis, data analysis, and project reporting,welcome to consult for free!

Biotech PackTraditionalVaccineCharacterization Content